GSK plc Share Price

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 16:35:16 13/06/2024 BST 5-day change 1st Jan Change
1,610 GBX +0.31% Intraday chart for GSK plc -1.83% +11.02%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 31.66B 40.4B 3,166B Sales 2025 * 33.63B 42.91B 3,363B Capitalization 65.66B 83.77B 6,566B
Net income 2024 * 5.57B 7.11B 557B Net income 2025 * 6.52B 8.31B 652B EV / Sales 2024 * 2.46 x
Net Debt 2024 * 12.23B 15.6B 1,223B Net Debt 2025 * 8.75B 11.17B 875B EV / Sales 2025 * 2.21 x
P/E ratio 2024 *
11.7 x
P/E ratio 2025 *
10.1 x
Employees 70,212
Yield 2024 *
3.77%
Yield 2025 *
3.91%
Free-Float 94.54%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.31%
1 week-1.83%
Current month-8.86%
1 month-11.05%
3 months-5.03%
6 months+10.59%
Current year+11.02%
More quotes
1 week
1 595.00
Extreme 1595
1 640.50
1 month
1 588.00
Extreme 1588
1 823.50
Current year
1 453.20
Extreme 1453.2
1 823.50
1 year
1 302.60
Extreme 1302.6
1 823.50
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 30/04/10
Director of Finance/CFO 62 30/04/23
Compliance Officer - 31/07/95
Members of the board TitleAgeSince
Director of Finance/CFO 62 30/04/23
Chairman 66 31/08/19
Director/Board Member 62 31/12/17
More insiders
Date Price Change Volume
13/06/24 1,610 +0.31% 3,808,062
12/06/24 1,605 -0.62% 10,253,390
11/06/24 1,615 -0.37% 20,843,350
10/06/24 1,621 -0.49% 4,498,323
07/06/24 1,629 -0.67% 6,977,567

Delayed Quote London S.E., June 13, 2024 at 04:35 pm

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.1 GBP
Average target price
20.36 GBP
Spread / Average Target
+26.49%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW